Clinical Trial

A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 10 locations 2026-07-29
Trial Details
NCT Number NCT06319456
Lead Sponsor Ascentage Pharma Group Inc.
Conditions CLL/SLL
Enrollment 344 participants
Start Date 2024-04-07
Primary Completion 2027-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-28